BAGSVAERD, DENMARK--(Marketwire - April 06, 2012) - Novo Nordisk today announced that the US
Food and Drug Administration (FDA) has
approved to update the product label for Victoza® (liraglutide [rDNA]
injection) to include data showing superior blood sugar control and weight
reduction when compared to Januvia® (sitagliptin).
Company announcement 22 2012:
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Novo Nordisk A/S via Thomson Reuters ONE